Comparison of Procedural Sedation in TEE - Trial NCT06129188
Access comprehensive clinical trial information for NCT06129188 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Anesthesia. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Alabama at Birmingham
Timeline & Enrollment
Phase 1
Jan 01, 2024
Jun 01, 2024
Primary Outcome
Blood pressure, physiologic parameter,Heart rate, physiologic parameter
Summary
The objective of this proposal is to conduct a prospective randomized study comparing the
 utility of sedating patients undergoing transesophageal echocardiographic studies with a
 novel, recently-FDA-approved sedative agent, remimazolam, versus the sedative used in our
 current practice at UAB, propofol. This study will investigate whether remimazolam offers any
 benefit over current care vis-à-vis hemodynamics or efficiency/throughput.
 
 This study will be conducted at the University of Alabama at Birmingham. All outpatients and
 inpatients scheduled for elective/non-emergent TEE in the UAB Heart and Vascular Center TEE
 lab will be considered for enrollment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06129188
Non-Device Trial